In the realm of genetic testing and diagnostics, advancements have been monumental, offering new insights into complex diseases and conditions. One such advancement is the utilization of fluorescence in situ hybridization (FISH) techniques, particularly in identifying chromosomal abnormalities, including the translocation t(15;17) associated with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). The FISH – t(15;17) or LSI PML/RARA test is a critical diagnostic tool in the genetic lab arsenal, providing vital information for the diagnosis, prognosis, and treatment planning of APL.
Understanding FISH – t(15;17) or LSI PML/RARA Test
The FISH – t(15;17) or LSI PML/RARA test is a targeted genetic test designed to detect the specific chromosomal translocation between chromosomes 15 and 17, which results in the fusion gene PML/RARA. This fusion gene is a hallmark of acute promyelocytic leukemia and is present in approximately 90% of APL cases. The test employs fluorescent probes that bind to the DNA sequences of interest, allowing for the visualization of this genetic anomaly under a fluorescence microscope.
Symptoms of Acute Promyelocytic Leukemia
Acute promyelocytic leukemia manifests with a range of symptoms, which can often be nonspecific and mimic those of other conditions. Recognizing these symptoms early can lead to prompt testing and diagnosis, significantly improving treatment outcomes. Common symptoms include:
- Fatigue and weakness
- Easy bruising or bleeding
- Fever and infections
- Weight loss or loss of appetite
- Shortness of breath
- Petechiae (small red spots under the skin)
It’s important to note that these symptoms can arise from a variety of health issues, making specific diagnostic tests like the FISH – t(15;17) or LSI PML/RARA test crucial in confirming the presence of APL.
Importance of the FISH – t(15;17) or LSI PML/RARA Test in Diagnosis and Treatment
The FISH – t(15;17) or LSI PML/RARA test plays a pivotal role not only in diagnosing APL but also in guiding treatment decisions. The presence of the PML/RARA fusion gene indicates a specific treatment protocol that includes all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which have been shown to be highly effective in treating APL. Additionally, the test can be used to monitor disease progression and response to treatment, making it an invaluable tool in managing the disease.
Test Cost
The cost of the FISH – t(15;17) or LSI PML/RARA test is 1200 AED. This investment in your health provides critical information that can significantly influence treatment decisions and outcomes. Considering the specialized nature of the test and its importance in the accurate diagnosis and management of APL, the cost reflects the value and precision it offers to patients and healthcare providers alike.
Conclusion
Acute promyelocytic leukemia is a serious and potentially life-threatening condition that requires accurate diagnosis and targeted treatment. The FISH – t(15;17) or LSI PML/RARA test is a key diagnostic tool in identifying the genetic marker associated with APL, facilitating prompt and effective treatment. If you or someone you know is experiencing symptoms consistent with APL, it is crucial to seek medical advice and consider genetic testing as part of the diagnostic process. For more information on the FISH – t(15;17) or LSI PML/RARA test, please visit DNA Labs UAE.
